Affiliation:
1. V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation, Moscow; I.M. Sechenov First Moscow State Medical University
2. V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation, Moscow
3. V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian Federation, Moscow; Pirogov Russian National Research Medical University
Abstract
Aim:to determine the clinical significance of vascular endothelial growth factors VEGF-A, VEGF-D, PlGF-1 to assess the risk of cardiovascular complications in heart recipients.Materials and methods.103 patients, aged 16 to 73 years, 85 males and 18 females. 65 recipients (47 men and 18 women) had dilated cardiomyopathy, 38 – coronary heart disease (CHD). The concentration of VEGF-A, VEGF-D, PlGF-1 was measured using xMAP technology with sets of reagents Simplex ProcartaPlex™.Results.After HTx the level of VEGF-A significantly decreased, p = 0.001. There were no correlations between the levels of VEGF-A, VEGF-D and PlGF-1 with age, gender and diagnosis. After HTx VEGF-A level was higher in recipients with ACR than in those without it (p = 0.001). ACR frequency was significantly higher in patients with high VEGF-A level (≥316.5 pg/ml, RR = 5.8 ± 0.5, AUC = 0.779). After HTx PlGF-1 level was higher in recipients with ACR too (p = 0.039). ACR frequency was significantly higher in patients with high PlGF-1 level (≥5.33 pg/ml, RR = 1.8 ± 0.5, AUC = 0.65). There were no correlations between VEGF-D level with ACR and all three biomarkers with AMR. ACR frequency was significantly higher with both high VEGF-A and PlGF-1 levels (RR = 6.4).Conclusion.Serum levels of VEGF-A and PlGF-1 after HTx may be regarded as indicators of increased risk of ACR.
Publisher
V.I. Shimakov Federal Research Center of Transplantology and Artificial Organs
Subject
Transplantation,Immunology and Allergy
Reference14 articles.
1. Lund LH, Edwards LB, Kucheryavaya AY, Dipchhand AI, Benden C, Christie JD et al. The registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report – 2013; Focus Theme: Age J Heart Lung Transplant. 2013; 32 (10): 951–964. DOI: 10.1016/j.healun.2013.08.006.PMID: 24054804.
2. Richter B, Koller L, Hohensinner PJ, Zorn G, Brekalo M, Berger R et al. A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure. Int J Cardiol. 2013; 168 (2): 1251–1257. DOI: 10.1016/j.ijcard.2012.11.052. PMID: 23218577.
3. Frick M, Antretter H, Pachinger O, Pölzl G. Biomarker for diagnosis of rejection after heart transplantation Herz. 2010; 35 (1): 11–16. DOI: 10.1007/s00059-010 3309-3.PMID: 20140784. Labarrere CA, Jaeger BR. Biomarkers of heart transplant rejection: the good, the bad, and the ugly Transl Res. 2012; 159 (4): 238–251. DOI: 10.1016/j.trsl.2012.01.018. PMID: 22424428
4. Kimura K, Hashiguchi T, Deguchi T, Horinouchi Sh, Uto T, Oku H et al. Serum VEGF – as a prognostic factor of atherosclerosis. Atherosclerosis. 2007; 194: 182–188. DOI: http://dx.doi.org/10.1016/j.atherosclero- sis.2006.07.025.
5. Daly KP, Seifert ME, Chandraker A, Zurakowski D, Nohria A, Givertz MM et al. VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant. 2013; 32 (1): 120–128. DOI: 10.1016/j.healun.2012.09.030.PMID: 23260712.